NCT03196934No Longer Available不适用
A Multicenter, Open-label, Flexible Dose Study to Assess the Long-term Safety of Pharmaceutical Cannabidiol Oral Solution as an Adjunctive Treatment for Pediatric Subjects With a Treatment-resistant Seizure Disorder Who Complete INS011-14-029 or Part A of INS011-15-054
MultiCare Health System Research Institute0 个研究点开始时间: 2017年6月23日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- No Longer Available
- 发起方
研究概览
简要总结
To allow subjects who have completed Insys 030 extension study to continue to take Cannabidiol oral solution.
详细描述
To allow subjects who have completed Insys 030 extension study (A multicenter, open-label, flexible dose study to assess the long-term safety of pharmaceutical Cannabidiol Oral Solution as an adjunctive treatment for pediatric subjects with a treatment-resistant seizure disorder who complete INS011-14-029 or Part A of INS011-15-054) to continue to take Cannabidiol oral solution.
研究设计
- 研究类型
- Expanded Access
入排标准
- 年龄范围
- 1 Year 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Completed the Insys 030 protocol
- •Compliant in drug study procedures
- •Non-pregnant females of child bearing age, willing to utilize a double-barrier method of birth control during treatment and for 30 days after treatment has ended
排除标准
- •Failure to follow study procedures in Insys 030
- •Pregnant females
研究者
相似试验
终止
3 期
A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett SyndromeRett SyndromeRTTNCT04252586Jazz Pharmaceuticals21
已完成
3 期
Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure DisorderSeizuresNCT02318602INSYS Therapeutics Inc52
终止
2 期
Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence SeizuresChildhood Absence EpilepsyNCT03355300Radius Pharmaceuticals, Inc.11
终止
2 期
A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to PoziotinibNSCLCBreast CancerNCT03744715Spectrum Pharmaceuticals, Inc7
已完成
1 期
Oral Cannabidiol Effect on Blood Pressure in Hypertensive PatientsHypertensionNCT05346562University of Split, School of Medicine70